What is ARA-290, and why are people interested?

ARA-290, also called cibinetide, is a short peptide designed from the structure of erythropoietin, or EPO. EPO stimulates red blood cell production. Researchers developed ARA-290 to investigate tissue-protection effects without that blood-cell effect. Its proposed target is a signaling system called the innate repair receptor. Design and early human research.

The interest in neuropathy comes from a practical question: could treatment help damaged small nerve fibers recover, as well as ease symptoms? Human studies have measured both. Some findings are encouraging, but improved nerve images and reliable relief of pain are different outcomes.

What did the sarcoidosis studies find?

Sarcoidosis is an inflammatory disease that can affect small nerve fibers. Three small placebo-controlled studies in this setting provide much of the clinical evidence. Their results need to be read measure by measure.

The 2012 pilot involved 22 people. After four weeks of intravenous treatment, the ARA-290 group improved more on a small fiber neuropathy symptom questionnaire. Pain intensity and fatigue improved similarly with ARA-290 and placebo. The study therefore supports a symptom signal, but not a clear advantage on every outcome. 2012 pilot.

A 2013 study enrolled 38 people. Four weeks of injections under the skin were associated with improved corneal nerve measurements, neuropathy symptoms and pain interference with daily life. Average pain intensity did not improve more than placebo. At the nine-month assessment, pain-interference scores were no longer significantly different from their starting values. 2013 study.

That paper also has a published correction. An arithmetic error made its absolute corneal nerve-area values too small. The authors supplied a correction factor in 2016. This is a reason to use the corrected measurements, not to treat the paper as retracted. Published erratum.

The 2017 dose-ranging trial randomized 64 people. Its main outcome was corneal nerve fiber area after 28 days. The middle dose improved that measure compared with placebo; the lower and higher doses did not reach statistical significance. A skin marker of growing nerve fibers also increased at the middle dose. However, pain improved in all groups, and the reported placebo-adjusted pain difference in participants with moderate-to-severe pain was not statistically significant (P = 0.157). 2017 trial.

A microscope measurement in the cornea, the clear surface at the front of the eye, can help researchers study small fibers. It does not establish that nerves throughout the body have recovered or that a person will have lasting pain relief. The trial record includes posted outcomes and adverse events.

Was ARA-290 studied in diabetes too?

Yes. A separate placebo-controlled study enrolled 49 people with type 2 diabetes and painful neuropathy; 48 were included in the analysis. It reported better PainDetect symptom scores and a small improvement in a blood-sugar marker. The overall corneal nerve-density change was not statistically significant. A later subgroup analysis found an increase within the treated group whose starting nerve density was low. That is more limited than a positive nerve-repair result across the whole trial. Diabetes study.

This published study used registry number NTR3858. It should not be confused with NCT01933529, a separate metabolic study whose record lists an estimated 24 participants, an unknown current status and no posted results.

A 2020 open-label study in diabetic macular edema, swelling in the retina, enrolled nine people, with eight completing treatment. After 12 weeks, average visual acuity, retinal thickness, retinal sensitivity and tear production had not improved. A vision-related questionnaire improved, but there was no placebo group. This does not establish an effective treatment for diabetic eye disease. Macular-edema study.

What about reports from individual patients?

A September 2026 paper described three people with sensory problems after dental procedures. Their symptoms improved after local treatment combining ARA-290, BPC-157 and TB-500 with a steroid and local anesthetic. All received the combination, with no comparison group. The authors could not separate the effects of the individual drugs from each other or from natural recovery. These are documented observations, but they cannot show that ARA-290 caused the improvement. Three-case report.

How much do we know about safety?

The small sarcoidosis studies provide some short-term tolerability information, but the record is not free of serious events. In the 2017 trial, serious events occurred in three treated participants and none receiving placebo; two affected participants were in the lowest-dose group, with events judged unrelated, and one was in the highest-dose group, with suicidal ideation judged possibly related. Posted safety results; full trial report.

The diabetes paper reports four serious adverse events in the ARA-290 arm, two judged possibly related. Treatment was stopped in one person with worsening kidney function. It also describes a fatal heart attack after a severe infection, which the safety committee judged unrelated. These findings do not establish causation, but they make a blanket claim that ARA-290 is safe inappropriate. Full safety report.

Longer-term effects, repeat courses and safety in other patient groups remain uncertain. Trial findings also cannot establish the identity, sterility or safety of an unrelated product sold under the same name.

What is its regulatory position?

The FDA list updated May 14, 2026 places cibinetide in category 3 for substances nominated for section 503A compounding. This means the nomination lacked adequate supporting information. It is not drug approval or a positive decision that the substance belongs on the final compounding list. Current FDA list.

Cibinetide also has European orphan-designation records. The EMA explicitly distinguishes an orphan designation from a marketing authorization. Access must be checked for the exact product and country; a research listing or a prescription alone does not answer that question. EMA explanation.

What would strengthen the evidence?

Larger trials would need to show meaningful improvements in symptoms and daily function, establish how long they last, and characterize harms. We did not identify a confirmatory Phase 3 neuropathy trial in the sources checked.

Questions to bring to the clinical team

  • What is causing the neuropathy, and how closely does it match the people studied?
  • Is the proposed outcome less pain, better function or a change in a nerve measurement?
  • What supports this exact product and route, and what authorization applies?
  • How would benefit, adverse effects and stopping decisions be assessed?

Questions people ask

Does ARA-290 prove that damaged nerves can be repaired?

The trials reported changes in corneal nerve measurements and some symptoms. Those findings support further research, but they do not establish lasting repair throughout the body or reliable pain relief.

Is there human evidence for diabetic neuropathy?

Yes. A small placebo-controlled study reported improved symptom scores, but the overall corneal nerve-density result was not statistically significant. A favorable subgroup finding needs confirmation.

Do the short trials establish long-term safety?

No. Serious events were reported in treated participants, with differing assessments of whether treatment contributed. The studies are too small and short to establish long-term safety.

Does orphan designation mean cibinetide is approved?

No. Orphan designation supports development for a rare condition. It is separate from marketing authorization and does not establish lawful access to a particular product.

The evidence

Selected original studies, trial records and official sources. Related research is searchable on our Science page.

CONTROLLED TRIALHeij et al. ARA 290 in sarcoidosis-associated small fiber neuropathy (2012). PMID:23168581
CONTROLLED TRIALDahan et al. Symptoms and corneal nerve measurements in sarcoidosis (2013). PMID:24136731
CORRECTIONErratum to Dahan et al.: corneal nerve area calculation (2016). PMID:28059429
RANDOMIZED TRIALCulver et al. Cibinetide and small nerve fiber abundance in sarcoidosis (2017). PMID:28475703
POSTED TRIAL RESULTSSarcoidosis dose-ranging study, 64 participants. NCT02039687
CONTROLLED TRIALBrines et al. ARA 290 in type 2 diabetes and painful neuropathy (online 2014; journal issue 2015). PMID:25387363
TRIAL REGISTRYSeparate prediabetes and type 2 diabetes study; status unknown, no results posted. NCT01933529
OPEN-LABEL STUDYLois et al. Cibinetide for diabetic macular edema (2020). PMID:32674280
CASE REPORTFroum et al. Three dental nerve-injury cases using combined interventions (2026). PMID:42876687
REGULATORY SOURCEFDA. Substances nominated for section 503A compounding, updated May 14, 2026. Read source
REGULATORY SOURCEEMA. Cibinetide orphan designation for pancreatic islet graft loss; designation is not authorization. Read source

Sources checked November 9, 2026, including full clinical reports, the 2013 paper's erratum and current trial records. This is a selected evidence review, not a catalogue of every ARA-290 experiment. No article-specific medical review is claimed.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. ARA-290 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.